Chinese Journal of Cancerindexed by SCI
《癌症》杂志
BMC

doi: 10.5732/cjc.011.10281
Current development of the second generation of mTOR inhibitors as anticancer agents
Hong-Yu Zhou, Shi-Le Huang
Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130-3932, USA. shuan1@lsuhsc.edu
[Abstract] The mammalian target of rapamycin (mTOR), a serine/threonine protein kinase, acts as a “master switch” for cellular anabolic and catabolic processes, regulating the rate of cell growth and proliferation. Dysregulation of the mTOR signaling pathway occurs frequently in a variety of human tumors, and thus, mTOR has emerged as an important target for the design of anticancer agents. mTOR is found in two distinct multiprotein complexes within cells, mTORC1 and mTORC2. These two complexes consist of unique mTOR-interacting proteins and are regulated by different mechanisms. Enormous advances have been made in the development of drugs known as mTOR inhibitors. Rapamycin, the first defined inhibitor of mTOR, showed effectiveness as an anticancer agent in various preclinical models. Rapamycin analogues (rapalogs) with better pharmacologic properties have been developed. However, the clinical success of rapalogs has been limited to a few types of cancer. The discovery that mTORC2 directly phosphorylates Akt, an important survival kinase, adds new insight into the role of mTORC2 in cancer. This novel finding prompted efforts to develop the second generation of mTOR inhibitors that are able to target both mTORC1 and mTORC2. Here, we review the recent advances in the mTOR field and focus specifically on the current development of the second generation of mTOR inhibitors as anticancer agents.
Chinese Journal of Cancer 2012, Volume: 31, Issue 1, Page: 8-18
[ PDF Full-text ]
[ Html full-text ](PubMed Central)

[ PubMed ]

[Google Scholar]


Cite this article

Hong-Yu Zhou, Shi-Le Huang. Current development of the second generation of mTOR inhibitors as anticancer agents. Chin J Cancer.2012,31(1):8-18. doi:10.5732/cjc.011.10281

CJC Wechat 微信公众号

 

Editorial Manager


CJC adopts Editorial Manager to manage its submissions from Dec.18, 2014
 


 * EndNote Style of CJC



Editorial Manager


 

Year:

 

Month:


CJC is now published by BioMed Central

© Chinese Journal of Cancer

Sun Yat-sen University Cancer Center

651 Dongfeng Road East, Guangzhou 510060, P. R. China